Pharmacokinetics and Safety Profile of Tigecycline in Children Aged 8 to 11 Years With Selected Serious Infections: A Multicenter, Open-Label, Ascending-Dose Study

详细信息    查看全文

• 作者：Jay Purdy ; MD ; PhD¹ ; Sylvie Jouve ; PhD² ; Jean Li Yan ; MS³ ; Ivana Balter ; MD² ; Nathalie Dartois ; MD² ; C. Angel Cooper ; MS¹ ; Joan Korth-Bradley ; PharmD ; PhD⁴ ; ^{Joan.Korth-Bradley@Pfizer.com}
• 关键词：pediatrics ; pharmacokinetics ; tigecycline
• 刊名：Clinical Therapeutics
• 出版年：2012
• 出版时间：February 2012
• 年：2012
• 卷：34
• 期：2
• 页码：496-507.e1
• 全文大小：784 K

文摘

Background

Tigecycline, a broad-spectrum antibiotic used for treating serious bacterial infections in adults, may be suitable for pediatric use once an appropriate dosage is determined.

Objective

The aim of this study was to assess the pharmacokinetic (PK) properties, safety profile, and descriptive efficacy of tigecycline.

Methods

In this Phase II, multicenter, open-label clinical trial, children aged 8 to 11 years with community-acquired pneumonia (CAP), complicated intra-abdominal infection (cIAI), or complicated skin and skin structure infections (cSSSI) were administered tigecycline 0.75, 1, or 1.25 mg/kg.

Results

A total of 58 patients received ? dose of tigecycline (31 boys; 44 white; mean age, 10 years; mean weight, 35 kg); 47 had data from samples available for PK analysis. The mean (SD) PK values were: C_max, 1899 (2954) ng/mL; T_max, 0.56 (0.18) hour; between-dose AUC, 2833 (1557) ng ¡¤ h/mL; weight-normalized clearance, 0.503 (0.293) L/h/kg; and Vd_ss, 4.88 (4.84) L/kg. Overall clinical cure rates at test-of-cure were 94 % (16/17), 76 % (16/21), and 75 % (15/20) in the 0.75-, 1-, and 1.25-mg/kg cohorts, respectively. The rates of protocol violations were higher in the 1- and 1.25-mg/kg groups, resulting in higher proportions of indeterminate clinical cure assessments relative to the 0.75-mg/kg cohort (19 % and 15 % vs 0 % ). The most frequent adverse event was nausea, which occurred in 50 % of patients overall (29/58) and the prevalence of which was significantly higher in the 1.25-mg/kg group versus the 0.75-mg/kg group (65 % vs 18 % ; P = 0.007). Pharmacodynamic simulations using MIC data from an ongoing microbiological surveillance trial predicted that a dosage of 1.2 mg/kg q12h would lead to therapeutic target attainment levels of up to 82 % for the target AUC_0-24/MIC ratios.

Conclusion

A tigecycline dosage of ?.2 mg/kg q12h may represent the most appropriate dosage for subsequent evaluation in Phase III clinical trials in children aged 8 to 11 years with selected serious bacterial infections. identifier: .